June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Tear Film Biomarkers in Patients with Ocular Mucous Membrane Pemphigoid
Author Affiliations & Notes
  • Jesse Panthagani
    Ophthalmology, Birmingham and Midland Institute, Birmingham, Birmingham, United Kingdom
  • Rachel Caroline Vincent
    Ophthalmology, Birmingham and Midland Institute, Birmingham, Birmingham, United Kingdom
  • Anisha Sekaran
    Ophthalmology, Birmingham and Midland Institute, Birmingham, Birmingham, United Kingdom
  • Jose Manuel Romero del Hombre
    Ophthalmology, Birmingham and Midland Institute, Birmingham, Birmingham, United Kingdom
  • Nicholas Barnes
    University of Birmingham Institute of Clinical Sciences, Birmingham, West Midlands, United Kingdom
  • Graham R Wallace
    Ophthalmology, Birmingham and Midland Institute, Birmingham, Birmingham, United Kingdom
  • Saaeha Rauz
    Ophthalmology, Birmingham and Midland Institute, Birmingham, Birmingham, United Kingdom
  • Footnotes
    Commercial Relationships   Jesse Panthagani, None; Rachel Vincent, None; Anisha Sekaran, None; Jose Romero del Hombre, None; Nicholas Barnes, None; Graham Wallace, None; Saaeha Rauz, None
  • Footnotes
    Support  Fight for Sight small grant 24NE182
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1245. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jesse Panthagani, Rachel Caroline Vincent, Anisha Sekaran, Jose Manuel Romero del Hombre, Nicholas Barnes, Graham R Wallace, Saaeha Rauz; Tear Film Biomarkers in Patients with Ocular Mucous Membrane Pemphigoid. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1245.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Mucous membrane pemphigoid (OcMMP) is an immunobullous disease characterised by a progressive conjunctival fibrosis driven by inflammation. In over 50% of cases, disease progresses in the absence of clinically visible inflammation. The purpose of this study was to analyse tear washings to identify components of inflammation and fibrosis that could be used as putative biomarkers of disease activity and response to therapy.

Methods : Tear washings were obtained by applying 100μL 0.9% NaCl onto the ocular surface and aspirating with a lacrimal canula from 21 OcMMP patients (42 eyes; mean age 74.6(±8.9 SD) years, 14(66%) female, 17(81%) biopsy-positive) and 15 age-matched cataract patient controls(30 eyes; age 72.3(±10.9) years, 8(53%) female). Total protein content (DC Protein Assay (BioRad, USA)) was used to correct for the variation in sample volume. Matrix metalloproteinases (MMP) 8 and 9, myeloperoxidase (MPO), epithelial growth factor (EGF), interleukin (IL)-1β, 6, 8, 10, 13 and TNF-α were quantified with a Luminex Assay (Thermo Fisher Scientific, USA). Total aldehyde dehydrogenase (ALDH) activity was measured using BioVision PicoProbe™ ALDH assay. Statistical analyses were performed using GraphPad Prism 8 (Mann Whitney U non-parametric test).

Results : Based upon the cicatrising conjunctivitis assessment tool (CCAT©Score) the majority of OcMMP eyes had none/minimal inflammation (mean score 0.79±1.58SD) at the time of sampling and 29(69.0%) had >50% symblepharon. MMP8, MPO and IL-6 were significantly elevated whereas EGF was significantly lower in OcMMP versus controls (p=0.025, p=0.010, p=<0.001 and p=0.001 respectively, Figure 1). There was no significant difference in the other measured cytokines . Mean ALDH activity was higher in OcMMP eyes (0.4 vs 0.05 mAU/mg, p=0.025, Figure 2).

Conclusions : Despite the absence of clinically visible conjunctival inflammation significant differences in tear film MMP8, MPO, IL-6, EGF and ALDH expression were observed in OcMMP eyes compared to controls. MMP8 and MPO are primarily produced by neutrophils and macrophages. IL-6 is a pro-inflammatory cytokine playing a role in chronic inflammation. ALDH has been linked to progressive conjunctival fibrosis in OcMMP. Taken together, these data could represent a pharmacodynamic biomarker panel for OcMMP to enable measurement of treatment response to novel therapies, and as predictors of disease progression in quiescent eyes.

This is a 2021 ARVO Annual Meeting abstract.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×